Cryogenic OGS Ltd
544440Cryogenic OGS Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows.
The sharpest disagreement: profits are rising, but only 57% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (63 weeks in) while the P/E sits at the 100th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +33.3% year on year, and 57% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cryogenic OGS Ltd trades at ₹443, in a confirmed uptrend and 63 weeks into that stage. That is +65.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹275 to ₹443. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 63 of stage 2, confirmed. At ₹443 it trades +65.1% versus its 200-day average and sits at 100% of its 52-week range (₹275–₹443).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +61% while the NIFTY 500 moved −6% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Cryogenic OGS Ltd trades at 73.4× P/E, about the priciest it has ever traded. Its long-run median P/E is 28.8×, measured across 1.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 73.4× is about the priciest it has ever traded, against a long-run median of 28.8× measured over 1.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cryogenic OGS Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +24.2% | +23.1% | — | — |
| Profit | +66.7% | +35.7% | — | — |
| EPS | +22.9% | −55.6% | — | — |
4-Factor Sector Score
62.0/100 — rank 2 of 9 in Engineering - Light - General · 36% evidence confidence · provisional, ranked below fully-evidenced peers
Cryogenic OGS Ltd scores 62.0 out of 100 against the 9 companies it is compared with in Engineering - Light - General, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 19.7 + 20.9 + 10 + 11.4 = 62. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cryogenic OGS Ltd reported ₹20.0 Cr of revenue in the Mar 26 quarter, +5.3% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 15.5% a year. The last full year, FY26, came in at ₹41.0 Cr. The last four reported quarters add to ₹73.0 Cr.
FY26 revenue came in at ₹41.0 Cr (+24.2% on the year), capping 4 years at 15.5% compound. The latest quarter (Mar 26) printed ₹20.0 Cr, +5.3% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +33.4% growth against the decade's 15.5% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cryogenic OGS Ltd's operating margin is 29.0% in the Mar 26 quarter, +7.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 19.0% to 28.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 29.0%, +7.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 19.0%–28.0%, and FY26's 28.0% is the top of that band — a record year.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cryogenic OGS Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, +33.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹10.0 Cr. The 4-year compound rate is 35.1%. That is 20.0% of the quarter's revenue.
Mar 26 profit was ₹4.0 Cr, +33.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹10.0 Cr (+66.7%), and the 4-year compound rate is 35.1%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 57% of Cryogenic OGS Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹8.0 Cr of operating cash against ₹10.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹−4.0 Cr was left as free cash.
FY26: operating cash of ₹8.0 Cr against reported profit of ₹10.0 Cr, leaving free cash of ₹−4.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 57% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 57%: the cash cycle stretched 198 days between FY22 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 198 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cryogenic OGS Ltd's cash conversion cycle runs 138 days in FY26, up from −60 days in FY22. Capital spending ran ₹14.0 Cr over the last 3 years. At FY26 sales of ₹41.0 Cr each day of that cycle holds about ₹0.1 Cr, so roughly ₹16.0 Cr sits inside the business at any moment.
FY26: debtors at 43 days, inventory at 138 days — roughly 4.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 138 days, looser than FY22's −60.
The full loop: cash goes out to suppliers and production on day 0; stock waits 138 days to sell; customers pay about 43 days after that; and suppliers themselves are paid at 44 days — netting out to the 138-day cycle.
In money terms: at FY26 sales of ₹41.0 Cr, each day of the cycle holds about ₹0.1 Cr — so the 138-day loop keeps roughly ₹16.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹14.0 Cr over the last 3 fiscal years against ₹3.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Cryogenic OGS Ltd earns a ROCE of 30% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 24.4% net margin on 0.61× asset turns.
FY26 ROCE is 30%.
Why the return is what it is — the wiring (FY26): 24.4% net margin × 0.61× asset turns × 1.24× balance-sheet leverage ≈ 18.5% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Cryogenic OGS Ltd carries ₹0.0 Cr of borrowings against ₹54.0 Cr of equity in FY26, a debt-to-equity of 0.00. Over 4 years borrowings went from ₹2.0 Cr to ₹0.0 Cr. Capital spending ran ₹14.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.0 Cr against equity of ₹54.0 Cr — a debt-to-equity of 0.00. Over 4 years borrowings went from ₹2.0 Cr to ₹0.0 Cr while capital spending ran ₹14.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Cryogenic OGS Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cryogenic OGS Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Axis Solutions Ltd511144 | 58.6/100Mixed-positive evidence69% evidence | LEADER | 20.2/35 Revenue 27.3% · PAT 16.7% · OPM change 2.7 pp 95% evidence | 16.6/25 ROCE 23.3% · OPM 12.6% 76% evidence | 9.3/20 P/E 98.8× · PEG — 15% evidence | 12.5/20 RS sector 0% · RS bench 170.3% · 1Y 2061.8%12 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 16.6 + 9.3 + 12.5 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Cryogenic OGS Ltdthis page544440 | 62.0/100Thin evidence · provisional36% evidence | TURNING | 19.7/35 Revenue — · PAT — · OPM change 7 pp 26% evidence | 20.9/25 ROCE 29.6% · OPM 29% 76% evidence | 10.0/20 P/E 73.4× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 100.5% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 19.7 + 20.9 + 10 + 11.4 = 62 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Omnitech Engineering LtdOMNI | 59.3/100Thin evidence · provisional38% evidence | BREAKING OUT | 22.0/35 Revenue — · PAT — · OPM change 4 pp 45% evidence | 16.9/25 ROCE 17.6% · OPM 30% 76% evidence | 10.4/20 P/E 72.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 22 + 16.9 + 10.4 + 10 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Shree Refrigerations Ltd544458 | 53.1/100Thin evidence · provisional36% evidence | LEADER | 17.4/35 Revenue — · PAT — · OPM change 2 pp 26% evidence | 14.0/25 ROCE 13.8% · OPM 26% 76% evidence | 10.8/20 P/E 65.6× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 60% · 1Y 56.8%12 of 12 weeks ahead 25% evidence |
| Exact sum: 17.4 + 14 + 10.8 + 10.9 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Tankup Engineers LtdTANKUP | 52.8/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.5/35 Revenue — · PAT — · OPM change 0.9 pp 26% evidence | 14.8/25 ROCE 19% · OPM 12.9% 95% evidence | 8.5/20 P/E 198× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 125.7% · 1Y —11 of 11 weeks ahead 25% evidence |
| Exact sum: 17.5 + 14.8 + 8.5 + 12 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Lloyds Engineering Works Ltd Partly PaidupLLOYDSENPP | 48.7/100Thin evidence · provisional8% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 10.1/25 ROCE — · OPM — 19% evidence | 11.1/20 P/E 34.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -38.5%0 of 12 weeks ahead to 2026-02-01 0% evidence | |
| Exact sum: 17.5 + 10.1 + 11.1 + 10 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Filtron Engineers Ltd531191 | 42.2/100Thin evidence · provisional35% evidence | ASLEEP | 19.2/35 Revenue — · PAT — · OPM change 243.4 pp 24% evidence | 4.4/25 ROCE 9.9% · OPM 10.5% 76% evidence | 9.6/20 P/E 79.4× · PEG — 15% evidence | 9.0/20 RS sector — · RS bench 0.6% · 1Y 176.7%0 of 6 weeks ahead 25% evidence |
| Exact sum: 19.2 + 4.4 + 9.6 + 9 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Sunita Tools Ltd544001 | 39.8/100Thin evidence · provisional45% evidence | BREAKING OUT | 14.9/35 Revenue — · PAT — · OPM change -9.7 pp 26% evidence | 10.2/25 ROCE 10.5% · OPM 15.2% 76% evidence | 8.9/20 P/E 110× · PEG — 15% evidence | 5.8/20 RS sector -35.6% · RS bench 38% · 1Y 38.8%7 of 7 weeks ahead 70% evidence |
| Exact sum: 14.9 + 10.2 + 8.9 + 5.8 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9C2C Advanced Systems LtdC2C | 33.2/100Thin evidence · provisional50% evidence | 13.4/35 Revenue — · PAT — · OPM change -47 pp 26% evidence | 5.3/25 ROCE 13.5% · OPM -8% 95% evidence | 11.5/20 P/E 24.2× · PEG — 15% evidence | 3.0/20 RS sector -60% · RS bench -48.9% · 1Y -65.2%0 of 4 weeks ahead to 2026-08-09 70% evidence | |
| Exact sum: 13.4 + 5.3 + 11.5 + 3 = 33.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Cryogenic OGS Ltd's share price today?
Cryogenic OGS Ltd trades at ₹443. The company is valued at ₹633 Cr. The stock sits at the very top of its 52-week range (₹275–₹443), +65.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 63 weeks in. — as of 1 October 2026.
What were Cryogenic OGS Ltd's latest quarterly results?
Cryogenic OGS Ltd reported revenue of ₹20.0 Cr and net profit of ₹4.0 Cr for the Mar 26 quarter. Revenue rose 5.3% and profit rose 33.3% year on year. Earnings per share were ₹3.13. The operating margin was 29.0%, 7.0 pp higher than a year earlier. — as of 1 October 2026.
What is Cryogenic OGS Ltd's revenue?
Cryogenic OGS Ltd reported revenue of ₹20.0 Cr in the Mar 26 quarter, +5.3% year on year. For the full FY26 fiscal year, revenue was ₹41.0 Cr (+24.2%). Over the last 4 years revenue compounded at 15.5% a year. — as of 1 October 2026.
What is Cryogenic OGS Ltd's profit?
Cryogenic OGS Ltd earned ₹4.0 Cr of net profit in the Mar 26 quarter, +33.3% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹10.0 Cr. The operating margin ran 29.0% in the latest quarter. — as of 1 October 2026.
What is Cryogenic OGS Ltd's market cap?
Cryogenic OGS Ltd's market capitalisation is ₹633 Cr at a share price of ₹443. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 1 October 2026.
What is Cryogenic OGS Ltd's P/E ratio?
Cryogenic OGS Ltd trades at a P/E of 73.4×, at the most expensive it has been in 1 years, against a long-run median of 28.8×. This is a comparison with the stock's own history, not a value call — as of 1 October 2026.
Does Cryogenic OGS Ltd pay a dividend?
No — Cryogenic OGS Ltd has recorded a dividend payout of 0% of profit in each of its last 5 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 1 October 2026.
Is Cryogenic OGS Ltd overvalued?
On its own history, Cryogenic OGS Ltd looks expensive: its P/E of 73.4× sits at the most expensive it has been in 1 years (long-run median 28.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 1 October 2026.
Is Cryogenic OGS Ltd growing?
Yes — Cryogenic OGS Ltd is growing: latest-quarter revenue +5.3% year on year, profit +33.3%, and the margin +7.0 pp at 29.0%. The 4-year compound rates are 15.5% (revenue) and 35.1% (profit). The earnings engine currently reads: improving — as of 1 October 2026.
How is Cryogenic OGS Ltd performing?
Cryogenic OGS Ltd is in a confirmed uptrend, 63 weeks in. Its latest quarter's revenue rose 5.3% and profit rose 33.3% year on year. This describes what the data did, not a rating. — as of 1 October 2026.
Is Cryogenic OGS Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 63 of stage 2), trading +65.1% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 1 October 2026.
Will Cryogenic OGS Ltd's share price go up?
This page publishes no price forecast for Cryogenic OGS Ltd. What it measures instead: the share price is ₹443, the price is in a confirmed uptrend 63 weeks in. Its P/E of 73.4× sits at the 100th percentile of its own 1-year range. — as of 1 October 2026.
Who owns Cryogenic OGS Ltd?
Promoters hold 74.3% of Cryogenic OGS Ltd, foreign institutions 0.0%, domestic institutions 1.6% and the public 24.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 1 October 2026.
Does Cryogenic OGS Ltd have too much debt?
No — Cryogenic OGS Ltd's debt-to-equity is 0.00. FY26 borrowings were ₹0.0 Cr against equity of ₹54.0 Cr. The returns on this page are earned, not borrowed — as of 1 October 2026.
What is Cryogenic OGS Ltd's capex?
Cryogenic OGS Ltd spent ₹14.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 1 October 2026.
What is Cryogenic OGS Ltd's cash flow?
Cryogenic OGS Ltd generated ₹8.0 Cr of operating cash flow in FY26 and ₹−4.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹10.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 1 October 2026.
Is Cryogenic OGS Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 57% of Cryogenic OGS Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹8.0 Cr against reported profit of ₹10.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 1 October 2026.
Where is Cryogenic OGS Ltd in its business cycle?
Cryogenic OGS Ltd's FY26 operating margin was 28.0%, against a 5-year band of 19.0%–28.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 29.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 1 October 2026.
What could break the Cryogenic OGS Ltd story?
The sharpest disagreement: profits are rising, but only 57% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 1 October 2026.
Is Cryogenic OGS Ltd a stock worth studying right now?
This is not investment advice. The machine read: Cryogenic OGS Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 1 October 2026.
Not SEBI Registered !! Not Investment advice !!